ORION Sante   Report issue

Academic/Hospital Phase 1 Phase 4
Founded: France

Organization Overview

First Clinical Trial
2002
NCT00761371
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Orion Biotechnology Polska Sp. z o.o.

Active Ingredients

Drugs in Phase 4 Trials (1)

imiquimod (aldara) (1 trial)

Drugs in Phase 1 Trials (1)

ob-002 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Warts (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2